Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. Overall, 5× more...
| Autores: | ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Tipo de documento: | Artículo |
| Fecha de publicación: | 2016 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Lenguaje: | Inglés |
| OAI Identifier: | oai:ddd.uab.cat:185773 |
| Acceso en línea: | https://ddd.uab.cat/record/185773 https://dx.doi.org/urn:doi:10.1093/annonc/mdw020 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | Pancreatic cancer Positron emission tomography Nab -paclitaxel Gemcitabine Metabolic response |
| _version_ | 1878742132550795264 |
|---|---|
| author | Ramanathan, R. K. |
| author2 | Goldstein, D. Korn, R. L. Arena, F. P Moore, M. Siena, S. Teixeira, L. Tabernero, Josep|||0000-0002-2495-8139 Van Laethem, J.-L. Liu, H. McGovern, D. Lu, B. Von Hoff, D. D. |
| author2_role | author author author author author author author author author author author author |
| author_browse | Arena, F. P Goldstein, D. Korn, R. L. Liu, H. Lu, B. McGovern, D. Moore, M. Ramanathan, R. K. Siena, S. Tabernero, Josep|||0000-0002-2495-8139 Teixeira, L. Van Laethem, J.-L. Von Hoff, D. D. |
| author_facet | Ramanathan, R. K. Goldstein, D. Korn, R. L. Arena, F. P Moore, M. Siena, S. Teixeira, L. Tabernero, Josep|||0000-0002-2495-8139 Van Laethem, J.-L. Liu, H. McGovern, D. Lu, B. Von Hoff, D. D. |
| author_role | author |
| collection | Dipòsit Digital de Documents de la UAB |
| description | In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. Overall, 5× more patients had a metabolic response by PET compared with RECIST. PET may be a more sensitive measure of response than radiographic modalities. In the phase III MPACT trial, nab -paclitaxel plus gemcitabine (nab -P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial. Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized 1:1 to receive nab -P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity. PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients (252 of 257) had ≥2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in the nab -P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best response at any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56; P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolic response rate (best response and week 8 response) was higher for nab -P + Gem (best response: 72% versus 53%, P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab -P + Gem versus Gem alone, including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%; P < 0.001). Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher for nab -P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associated with longer survival, and more patients experienced a metabolic response than a RECIST-defined response. NCT00844649. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_f09f6aa9ed2a009ca9d2db40a2f7f4ae |
| institution | Universitat Autònoma de Barcelona |
| instname_str | Universitat Autònoma de Barcelona |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:ddd.uab.cat:185773 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| reponame_str | Dipòsit Digital de Documents de la UAB |
| spelling | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas Ramanathan, R. K. Goldstein, D. Korn, R. L. Arena, F. P Moore, M. Siena, S. Teixeira, L. Tabernero, Josep|||0000-0002-2495-8139 Van Laethem, J.-L. Liu, H. McGovern, D. Lu, B. Von Hoff, D. D. Pancreatic cancer Positron emission tomography Nab -paclitaxel Gemcitabine Metabolic response In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. Overall, 5× more patients had a metabolic response by PET compared with RECIST. PET may be a more sensitive measure of response than radiographic modalities. In the phase III MPACT trial, nab -paclitaxel plus gemcitabine (nab -P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial. Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized 1:1 to receive nab -P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity. PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients (252 of 257) had ≥2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in the nab -P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best response at any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56; P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolic response rate (best response and week 8 response) was higher for nab -P + Gem (best response: 72% versus 53%, P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab -P + Gem versus Gem alone, including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%; P < 0.001). Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher for nab -P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associated with longer survival, and more patients experienced a metabolic response than a RECIST-defined response. NCT00844649. https://ddd.uab.cat/record/185773 https://dx.doi.org/urn:doi:10.1093/annonc/mdw020 |
| spellingShingle | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas Ramanathan, R. K. Pancreatic cancer Positron emission tomography Nab -paclitaxel Gemcitabine Metabolic response |
| title | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| title_full | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| title_fullStr | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| title_full_unstemmed | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| title_short | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| title_sort | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas |
| topic | Pancreatic cancer Positron emission tomography Nab -paclitaxel Gemcitabine Metabolic response |
| topic_facet | Pancreatic cancer Positron emission tomography Nab -paclitaxel Gemcitabine Metabolic response |
| url | https://ddd.uab.cat/record/185773 https://dx.doi.org/urn:doi:10.1093/annonc/mdw020 |